During any acute illness, glucose regulation is lost
and hyperglycemia develops due to insulin resistance and an absolute or
relative insulin deficiency [1,2]. Counter regulatory hormones (growth
hormone, glucagon, cortisol, catechola-mines) and inflammatory cytokines
promote lipolysis and proteolysis and thus gluconeogenesis. Hepatic
insulin resistance prevails and there is abundant endogenous production of
glucose inspite of elevated glucose levels. Insulin-stimulated uptake of
glucose by peripheral tissues such as skeletal muscle, heart and adipose
tissue is decreased. Immobility further impairs the exercise stimulated
uptake of glucose in skeletal muscle.
Hyperglycemia, a frequent finding in the critically
ill, was thought to be an adaptive response to stress and was not treated.
Recently, it has been recognised to be a marker of poor outcome [3]. Among
patients with trauma, stroke, myocardial infarction, and many other such
acute illnesses, hyperglycemia has been shown to increase morbidity and
mortality [4-7].
Hyperglycemia stimulates a cascade of pro-inflammatory
events [1], is prothrombotic, and increases oxidative stress by lipid
peroxidation. It promotes infection by decreasing neutrophil phago-cytic
activity and the oxidative burst of leukocytes. In laboratory studies,
exacerbation of ischemic brain injury, myocardial cell apoptosis due to
reactive oxygen species and adverse effects on pulmonary and renal tissue
due to free radical injury have been seen [7]. Insulin therapy seems to
counter these harmful effects of hyperglycemia with potent
anti-inflammatory effects [1]. Levels of mannose-binding lectin and C
reactive protein are lowered by insulin [2]. Insulin lowers blood glucose,
mainly by stimulation of skeletal muscle glucose uptake, but is unable to
reverse the hepatic insulin resistance. Insulin is known to lower free
fatty acids and normalise endothelial function as also being anabolic and
cardio-protective.
Evidence in Critically Ill Adults
In 2001,Van den Berghe, et al. [8] from Leuven,
Belgium, randomized adult patients receiving mechanical ventilation in a
surgical intensive care unit (ICU) to maintain blood glucose between 80 to
110 mg/dL using insulin infusion in the ‘intensive insulin therapy’ arm or
between 180 to 200 mg/dL in the ‘conventional therapy’ arm. A 42%
reduction in ICU mortality was seen with intensive insulin therapy; this
was entirely attributable to reduction of deaths in patients staying in
the ICU for more than five days. Intensive insulin therapy reduced
episodes of septicaemia by 46%, new onset acute renal failure by 41%,
median number of red cell transfusions by 50%, critical-illness
polyneuropathy by 44% and also the duration of mechanical ventilation and
intensive care
Several subsequent studies on this intervention;
however, yielded conflicting results. The substantial benefits obtained in
the Leuven study could not be consistently replicated and a higher
incidence of hypoglycemia (blood glucose <40 mg/dL) was noted. In a mixed
medical-surgical population of patients studied by Krinsley [9], a benefit
was seen with reduction in hospital mortality, new onset renal failure,
number of patients requiring red blood cell transfusions and length of ICU
stay. No increase in episodes of hypoglycemia was seen. Van den Berghe,
et al. [10] conducted a randomized, controlled study of tight glycemic
control in a medical ICU in 1200 adult patients. While there was no
decrease in hos-pital mortality with tight glycemic control, a
signi-ficant reduction in new-onset renal failure, duration of mechanical
ventilation, ICU and hospital stay were noted. Patients staying in the ICU
for less than 3 days had a higher mortality with tight glycemic control
while the reverse was true for those staying more than 3 days; a
significantly higher incidence of hypoglycemia was seen in the study
group (18.7% vs 3.1%). Treggiari, et al. [11] studied the
outcome among 10,456 patients admitted to medical, surgical and trauma
ICUs at a single centre over three consecutive time periods with differing
glycemic control proto-cols; no protocol, target glucose 80 to 130 mg/dL
and target glucose 80 to 110 mg/dL. There was no mortality benefit with
tight glycemic control, rather an increase in mortality was noted in
patients staying in the ICU for less than three days and the incidence of
hypoglycemia increased fourfold. Conflicting results were obtained in two
studies in the Asian population, with benefit from tight glycemic control
demonstrated by Wang, et al. [12] and no benefit demonstrated by
Arabi, et al. [13]. Two large multi-centre studies were
designed to resolve the conflic-ting results obtained in these single
centre studies. In a multicentric study in Germany conducted across 18
multidisciplinary ICUs [14], tight glycemic control in patients with
severe sepsis resulted in an increase in the rate of hypoglycemia to
unacceptably high level (4.1% to 17%). The study was terminated after the
first interim analysis for safety reasons. Similarly, a multicentric
European study from 19 centers of 7 countries [15] documented a fourfold
increase in the rate of hypoglycemia with intensive insulin therapy as
against conventional therapy (9.8% vs 2.7%) with no mortality
benefit.
A meta-analysis of twenty-nine randomized controlled
studies with data for over 8000 adult patients comparing tight glucose
control (blood sugar <150 mg/dL) using insulin infusion or usual glucose
control, reported no difference in hospital mortality (21.6% vs
23.3%) [16]. Further stratifi-cation of results based on setting (medical,
surgical, or medical-surgical) or degree of glucose control (very tight;
blood glucose maintained
≤110mg/dL or
moderately tight;
Another dimension of deranged glucose regulation in
critically ill children, variablility in glucose level and its adverse
effect on outcome was elucidated in further studies [27,28]. In a
retrospective study by Wintergrest, et al. [27], glucose
variability was calculated as an index based on consecutive glucose values
and reflected the fluctuations in glucose values. Higher glucose
variability was associated with a significantly higher hospital length of
stay and mortality. Hirshberg, et al. [28] also found that
hyperglycemia and glucose variability were significantly associated with
mortality, increased hospital length of stay and risk of nosocomial
infections. No glucose control protocol was in vogue when these studies
were conducted. Unfortunately, these studies do not give any data
regarding the nutrition, steroids, vasoactive infusions etc. used, which
might have affected glucose levels.
Though strict glycemic control has been accepted easily
as a standard of care among adults, the same is not true for pediatric
patients. A survey among the pediatric intensivists in the UK [29], and a
prospective study from the PICUs of Australia and New Zealand [30] showed
neither uniform glucose con-trol regimes nor consensus regarding levels of
hyperglycemia requiring therapy.
Preissig, et al. [31] instituted a protocol to
control hyperglycemia in a PICU. Blood glucose was maintained between 80
to 140 mg/dL using insulin infusion as and when necessary. On an average,
51% of the children were hyperglycemic, most developed this on day 2 of
PICU admission and a mean of 5.4 hours were required to correct the
hyperglycemia with insulin infusion. This study highlighted that it was
feasible and safe to institute glycemic control in critically ill children
without any significant increase in the episodes of hypoglycemia.
The single randomized controlled study of targe-ting
age-adjusted normoglycemia using insulin infusion in pediatric patients
was published by Vlasselaers, et al. [32]. 700 children admitted to
the PICU at Leuven were randomly assigned to either intensive insulin
group (target glucose 50-80 mg/dL in infants and 70-100 mg/dL in children)
or conventional group (insulin to prevent blood glucose >215 mg/dL). This
intervention resulted in a shorter stay in the PICU, an attenuated
inflammatory response as indicated by C-reactive protein level on day 5
compared to baseline (P=0.07) and a lower mortality (3% vs
6%, P=0.038) with intensive insulin approach. However, a higher
incidence of hypoglycemia occurred in the patients in the intensive
insulin group (25%) as compared to the conventional group (1%).
In view of the high prevalence of hyperglycemia in
critically ill children, and lack of good quality data supporting its
treatment, large randomized controlled studies are required to evaluate
efficacy and safety of insulin in the management of critically sick
children. The results of at least three large randomized con-trolled
trials of strict glycemic control in pediatric patients are eagerly
awaited [33-35].
Epilogue
Those caring for sick children should be aware of the
high prevalence and dangers of hyperglycemia. Accepting hyperglycemia as
an adaptive response to critical illness and treating it only when it
crosses the renal threshold is not justified. Treating hyperglycemia with
insulin infusion as one of the many arms of modern day ‘intensive care’
seems necessary. However, the glucose target should be modest. Targeting
blood glucose levels in the ‘normal’ range; i.e., <110 mg/dL is difficult,
increases nursing activity significantly [36] and is fraught with the risk
of hypoglycemia. It is more appropriate to target a level of 110-150 mg/dL
[37,38]. With this range of blood glucose, the ill effects of
hyperglycemia are overcome while avoiding the dangers and difficulty of
achieving normoglycemia. In view of paucity of such studies in the
developing world with a high prevalence of malnutrition, extrapolation of
Western literature should be done with caution. Each PICU should implement
locally appropriate protocols of blood glucose control while providing
adequate nutrition. Training of the nursing staff to implement a protocol
of frequent monitoring of blood glucose at the bedside and fine adjustment
of insulin infusion is crucial to prevent not only hypoglycemia but also
excessive variations in the glucose level, which may be as harmful.
Key Messages
• Hyperglycemia is common in critically ill
children and is associated with a poor outcome.
• Treating hyperglycemia with insulin infusion,
taking care to avoid hypoglycemia, improves outcome.
|
References
1. Corstjens AM, Van der Horst ICC, Zijlstra JG, Johan
Groeneveld AB, Zijlstra F, Tulleken JE, et al. Hyperglycemia in
critically ill patients: marker or mediator of mortality? Crit Care.
2006;10:216.
2. Marik PE, Raghavan M. Stress-hyperglycemia, insulin
and immunomodulation in sepsis. Intensive Care Med. 2004;30:748-56.
3. Derde S, Vanhorebeek I, Van den Berghe G. Insulin
treat-ment in intensive care patients. Horm Res. 2009;71:2-11.
4. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress
hyperglycemia and increased risk of death after myocardial infarction in
patients with and without diabetes: a systematic overview. Lancet.
2000;355:773-8.
5. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC.
Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic
patients: a systematic overview. Stroke. 2001;32:2426-32.
6. Sung J, Bochicchio GV, Joshi M, Bochicchio K, Tracy
K, Scalea TM. Admission hyperglycemia is predictive of outcome in
critically ill trauma patients. J Trauma. 2005;59:80-3.
7. Srinivasan V, Spinella PC, Drott HR, Roth CL,
Helfaer MA, Nadkarni V. Association of timing, duration and intensity of
hyperglycemia with intensive care unit mortality in critically ill
children. Pediatr Crit Care Med. 2004; 5:329-36.
8. Van den Berghe G, Woulters P, Weekers F, Verwaest C,
Bruyninckx F, Schetz M, et al. Intensive insulin therapy in
critically ill. N Engl J Med. 2001;345: 1359-67.
9. Krinsley JS. Effect of an intensive glucose
management protocol on the mortality of critically ill adult patients.
Mayo Clin Proc. 2004;79:992-1000.
10. Van den Berghe G, Wilmer A, Hermans G, Meersseman
W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the
medical ICU. N Engl J Med. 2006; 354: 449- 61.
11. Treggiari MM, Karir V, Yanez ND, Weiss NS, Daniel
S, Deem SA. Intensive insulin therapy and mortality in critically ill
patients. Crit Care. 2008;12: R29.
12. Wang LC, Lei S, Wu YC, Wu JN, Wang LF, Guan TR,
et al. Intensive insulin therapy in critically ill patients. Zhongguo
Wei Zhong Bing Ji Jiu Yi Xue. 2006; 18:748-50.
13. Arabi YM, Dabbagh OC, Tamim HM, Al-Shimemeri,
Memish ZA, Haddad SH, et al. Intensive versus conven-tional insulin
therapy: A randomised controlled trial in medical and surgical critically
ill patients. Crit Care Med. 2008; 36:3190-7.
14. Brunkhorst FM, Engel C, Bloos F, Meier-Hellman A,
Ragaller M, Weiler N, et al. Intensive insulin therapy and
pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125-39.
15. Devos P, Preiser JC, Melot C. Impact of tight
glucose control by intensive insulin therapy on ICU mortality and the rate
of hypoglycemia: final results of the Glucontrol. Intensive Care Med.
2007;33:(Suppl 2):S189.
16. Wiener RS, Wiener DC, Larson RJ. Benefits and risks
of tight glucose control in critically ill adults: A meta analysis. JAMA.
2008;300:933-44.
17. The NICE-SUGAR study investigators. Intensive
versus conventional glucose control in critically ill patients. N Engl J
Med. 2009;360:1283-97.
18. Griesdale DEG, de Souza RJ, van Dam RM, Heyland DK,
Cook DJ, Malhotra A, et al. Intensive insulin therapy and mortality
among critically ill patients: a meta-analysis including NICE-SUGAR study
data. CMAJ. 2009; 180:821-7.
19. Egi M, Bellomo R, Stachowski E, French CJ, Hart G.
Variability of blood glucose concentration and short-term mortality in
critically ill patients. Anesthesiology. 2006;105:244-52.
20. Ali NA, O’Brien JM, Jr., Dungan K, Phillips G,
Marsh CB, Lemeshow S, et al. Glucose variability and mortality in
patients with sepsis. Crit Care Med. 2008; 36:2316-21.
21. Bagshaw SM, Bellomo R, Jacka MJ, Egi M, Hart GK,
George C. The impact of early hypoglycemia and blood glucose variability
on outcome in critical illness. Crit Care. 2009;13:R91.
22. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra
DF, Hoekstra JB, Devries JH. Glucose variability is associated with
intensive care unit mortality. Crit Care Med. 2010;38:838-42.
23. Faustino EV, Apkon M. Persistent hyperglycemia in
critically ill children. J Pediatr. 2005;146:30-4.
24. Branco RDG, Tasker RC. Glycemic level in
mechanically ventilated children with bronchiolitis. Pediatr Crit Care
Med. 2007;8:546-50.
25. Day KM, Haub N, Betts H, Inwald DP. Hyperglycemia
is associated with morbidity in critically ill children with meningococcal
sepsis. Pediatr Crit Care Med. 2008;9: 636-40.
26. Branco RG, Garcia PCR, Piva JP, Casartelli CH,
Seibel V, Tasker RC. Glucose level and risk of mortality in pediatric
septic shock. Pediatr Crit Care Med. 2005;6:470-2.
27. Wintergrest KA, Buckingham B, Gandrud L, Wong BJ,
Kache S, Wilson DM. Association of hyperglycemia, hypoglycemia and glucose
variability with morbidity and death in the paediatric intensive care
unit. Pediatrics. 2006;118:173-9.
28. Hirshberg E, Larsen G, van Duker H. Alterations in
glucose homeostasis in the pediatric intensive care unit: Hyperglycemia
and glucose variability are associated with increased mortality and
morbidity. Pediatr Crit Care Med. 2008; 9:361-6.
29. Nayak P, Lang H, Parslow RC, Morris K.
Hyperglycemia and insulin therapy in the critically ill child. Pediatr
Crit Care Med. 2009;10:303-5.
30. Yung M, Wilkins B, Norton L, Slater A. Glucose
control, organ failure, and mortality in pediatric intensive care. Pediatr
Crit Care Med. 2008;9:147-52.
31. Preissig CM, Hansen I, Roerig PL, Rigby MR. A
protocolized approach to identify and manage hyperglycemia in a pediatric
critical care unit. Pediatr Crit Care Med. 2008;9:581-8.
32. Vlasselaers D, Milants I, Desmet L, Wouters PJ,
Vanhorebeek I, van den Heuvel I, et al. Intensive insulin therapy
for patients in paediatric intensive care: a prospective, randomized
controlled study. Lancet. 2009;373:547-56.
33. Maintaining normal blood sugar levels in children
undergoing heart surgery to reduce the risk of infections and improve
recovery (The SPECS study). http://clinicaltrials.gov/ct2/show/NCT00443599.
Accessed October 10, 2010.
34. Macrae D, Pappachan J, Grieve R, Parslow R, Nadel
S, Schindler M, et al. Control of hyperglycemia in paediatric
intensive care (CHiP): study protocol. BMC Paediatrics. 2010;10:5.
35. Pediatric ICUs at Emory-Children’s Centre Glycemic
Control: The PedETrol Trial. http://clinicaltrials.gov/ct2/show/NCT01116752.
Accessed October 10, 2010.
36. Chwals WJ. Hyperglycemia management strategy in the
pediatric intensive care setting. Pediatr Crit Care Med. 2008;9:656-8.
37. Vincent J. Blood glucose control in 2010. 110 to
150 mg/dL and minimal variability. Crit Care Med. 2010;38:993-5.
38. Jeschke MG, Kraft R, Emdad F, Kulp GA, Williams FN,
Herndon DN. Glucose control in severely thermally injured pediatric
patients: what glucose range should be the target? Ann Surg.
2010;252:521-7.